相关实验视频

Updated: Sep 11, 2025

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

使用与miRNA106a相关的心脏向酸逆转心脏缩和心力衰竭

Ming Lu¹, Siqi Cai¹, Kyle Korolowicz²

¹Department of Biochemistry and Molecular Biology, Georgetown University Medical Center, Washington, District of Columbia, USA.

Clinical and translational medicine

|August 18, 2025

概括

一种新的心脏特异性 (CTP) 提供了miRNA106a,以逆转小鼠心力衰竭 (HF). 这种向治疗降低了导致心脏缩和炎症的基因的调节,为HF治疗提供了一种新的分子方法.

科学领域:

心血管生物学心血管生物学
分子医学是分子医学.
生物技术是生物技术.

背景情况:

心力衰竭 (HF) 影响了20%的40岁以上的成年人,由导致心肌细胞功能障碍的风险因素驱动.
目前的HF治疗方法往往不够,疾病进展很常见.
需要转向针对心肌细胞特定途径的分子方法.

研究的目的:

开发和测试一种新的心脏特异性药物输送系统,用于HF治疗.
研究由心肌细胞向 (CTP) 输送的miRNA106a的潜力,以逆转HF.
阐明HF逆转背后的分子机制.

主要方法:

一种心肌细胞向性 (CTP) 与miRNA106a结合,用于在小鼠HF模型中进行向性传递.
进行了体内生物分布和清除研究.
心肌细胞缩和HF参数在体内和体外进行了评估.

主要成果:

在小鼠中,CTP-miRNA106a特别在30分钟内将其货物运送到心脏.
在90%的接受治疗的小鼠中,CTP-miRNA106a逆转了angiotensin2/isoproterenol诱导的心脏缩.
两个关键的细胞内信号通路 (PLCβ1/PKC/IP3和NF-κB) 被确定为目标.

结论:

CTP-miRNA106a 是一流的心脏特异性治疗药物,可以逆转HF.
它通过特定的激酶通路降低了参与心脏缩和炎症的基因.
在临床前模型中,通过CTP对miRNA106a的向输送有效地逆转了HF.

关键词:

在 NF-kB 中.针对心脏的向酸.心脏衰竭是因为心脏衰竭.在miRNA治疗中使用miRNA治疗.

更多相关视频

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...